Roflumilast is the generic ingredient in two branded drugs marketed by Astrazeneca, Breckenridge, Hetero Labs Ltd Iii, Micro Labs, Mylan, Strides Pharma, and Torrent and, and is included in seven NDAs. There are five patents protecting this compound.
Drug patent litigation for ROFLUMILAST.
This ingredient has seventy-nine patent family members in thirty-six countries.
One supplier is listed for this compound. There are three tentative approvals for this compound.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
